» Articles » PMID: 20587022

Characterization of the Human Activin-A Receptor Type II-like Kinase 1 (ACVRL1) Promoter and Its Regulation by Sp1

Overview
Journal BMC Mol Biol
Publisher Biomed Central
Specialty Molecular Biology
Date 2010 Jul 1
PMID 20587022
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Activin receptor-like kinase 1 (ALK1) is a Transforming Growth Factor-beta (TGF-beta) receptor type I, mainly expressed in endothelial cells that plays a pivotal role in vascular remodelling and angiogenesis. Mutations in the ALK1 gene (ACVRL1) give rise to Hereditary Haemorrhagic Telangiectasia, a dominant autosomal vascular dysplasia caused by a haploinsufficiency mechanism. In spite of its patho-physiological relevance, little is known about the transcriptional regulation of ACVRL1. Here, we have studied the different origins of ACVRL1 transcription, we have analyzed in silico its 5'-proximal promoter sequence and we have characterized the role of Sp1 in the transcriptional regulation of ACVRL1.

Results: We have performed a 5'Rapid Amplification of cDNA Ends (5'RACE) of ACVRL1 transcripts, finding two new transcriptional origins, upstream of the one previously described, that give rise to a new exon undiscovered to date. The 5'-proximal promoter region of ACVRL1 (-1,035/+210) was analyzed in silico, finding that it lacks TATA/CAAT boxes, but contains a remarkably high number of GC-rich Sp1 consensus sites. In cells lacking Sp1, ACVRL1 promoter reporters did not present any significant transcriptional activity, whereas increasing concentrations of Sp1 triggered a dose-dependent stimulation of its transcription. Moreover, silencing Sp1 in HEK293T cells resulted in a marked decrease of ACVRL1 transcriptional activity. Chromatin immunoprecipitation assays demonstrated multiple Sp1 binding sites along the proximal promoter region of ACVRL1 in endothelial cells. Furthermore, demethylation of CpG islands, led to an increase in ACVRL1 transcription, whereas in vitro hypermethylation resulted in the abolishment of Sp1-dependent transcriptional activation of ACVRL1.

Conclusions: Our results describe two new transcriptional start sites in ACVRL1 gene, and indicate that Sp1 is a key regulator of ACVRL1 transcription, providing new insights into the molecular mechanisms that contribute to the expression of ACVRL1 gene. Moreover, our data show that the methylation status of CpG islands markedly modulates the Sp1 regulation of ACVRL1 gene transcriptional activity.

Citing Articles

Hereditary Hemorrhagic Telangiectasia with Recurrent Epistaxis, Telangiectasia, Hepatic Arteriovenous Malformation, and a Poorly Developed Middle Cerebral Artery in a Patient with a Novel Mutation in the ACVRL1 Gene.

Miki T, Ishikura T, Fujita N, Nakano T, Kimura H, Sumi-Akamaru H Intern Med. 2024; 64(3):477-480.

PMID: 38960693 PMC: 11867738. DOI: 10.2169/internalmedicine.3485-24.


Blood flow regulates acvrl1 transcription via ligand-dependent Alk1 activity.

Anzell A, Kunz A, Donovan J, Tran T, Lu X, Young S Angiogenesis. 2024; 27(3):501-522.

PMID: 38727966 DOI: 10.1007/s10456-024-09924-w.


Blood flow regulates transcription via ligand-dependent Alk1 activity.

Anzell A, Kunz A, Donovan J, Tran T, Lu X, Young S bioRxiv. 2024; .

PMID: 38328175 PMC: 10849739. DOI: 10.1101/2024.01.25.576046.


Deep sequencing of circulating miRNAs and target mRNAs level in deep venous thrombosis patients.

Wang Q, Chang Y, Yang X, Han Z IET Syst Biol. 2023; 17(4):212-227.

PMID: 37466160 PMC: 10439493. DOI: 10.1049/syb2.12071.


Clonal hematopoiesis with JAK2V617F promotes pulmonary hypertension with ALK1 upregulation in lung neutrophils.

Kimishima Y, Misaka T, Yokokawa T, Wada K, Ueda K, Sugimoto K Nat Commun. 2021; 12(1):6177.

PMID: 34702814 PMC: 8548396. DOI: 10.1038/s41467-021-26435-0.


References
1.
Roelen B, van Rooijen M, Mummery C . Expression of ALK-1, a type 1 serine/threonine kinase receptor, coincides with sites of vasculogenesis and angiogenesis in early mouse development. Dev Dyn. 1997; 209(4):418-30. DOI: 10.1002/(SICI)1097-0177(199708)209:4<418::AID-AJA9>3.0.CO;2-L. View

2.
BLOOM B, Humphries D, Kuang P, Fine A, Goldstein R . Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: regulation by TGF-beta. Biochim Biophys Acta. 1996; 1312(3):243-8. DOI: 10.1016/0167-4889(96)00043-2. View

3.
Almendro N, Bellon T, Rius C, Lastres P, Langa C, Corbi A . Cloning of the human platelet endothelial cell adhesion molecule-1 promoter and its tissue-specific expression. Structural and functional characterization. J Immunol. 1996; 157(12):5411-21. View

4.
Sanz-Rodriguez F, Fernandez-L A, Zarrabeitia R, Perez-Molino A, Ramirez J, Coto E . Mutation analysis in Spanish patients with hereditary hemorrhagic telangiectasia: deficient endoglin up-regulation in activated monocytes. Clin Chem. 2004; 50(11):2003-11. DOI: 10.1373/clinchem.2004.035287. View

5.
Finnson K, Parker W, Ten Dijke P, Thorikay M, Philip A . ALK1 opposes ALK5/Smad3 signaling and expression of extracellular matrix components in human chondrocytes. J Bone Miner Res. 2008; 23(6):896-906. DOI: 10.1359/jbmr.080209. View